2016 Fiscal Year Final Research Report
Development of effective BNCT drug by using supramolecular complexation
| Project/Area Number |
26350528
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biomedical engineering/Biomaterial science and engineering
|
|---|
| Research Institution | Osaka City University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
Masunaga Shin-ichiro 京都大学, 原子炉実験所, 教授 (80238914)
MAzuma Hideki 大阪市立大学, 大学院工学研究科, 講師 (80311918)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 薬物送達システム / ホウ素中性子捕捉療法 / がん治療 / 超分子化学 / 包接化合物 / ターゲティング / ナノメディシン / シクロデキストリン |
|---|
| Outline of Final Research Achievements |
A novel water-soluble complex between boron cluster carborane-kojic acid conjugate(CKA) and hydroxylpropyl-beta-cyclodextrin (HP-betaCD) hve been prepared. It was revealed that CKA-HP-betaCD complex inhibited the metastasis of melanoma cells in vivo. It was suggested that the inhibitory ability of CKA to HIF-1alpha contributed to suppress the matastasis. Furthermore, in this study, the quantitative evaluation of the CKA’s inhibitory ability was carried out by quantitative real-time PCR in vivo. From the results of real-time PCR, CKA remarkably suppressed melanoma metastasis to the brain among other organs.
|
| Free Research Field |
生体医工学・生体材料学
|
